Compounds for treating viral infections
By developing compounds of formula (I), the safety and drug metabolism problems of existing PI4K inhibitors in the treatment of viral infections were solved, low CYP3A4 inhibitory activity and high antiviral activity were achieved, and cells were improved by regulating the autophagy process Healthy, providing effective treatment for a variety of viral infections and autophagy-related diseases.
Patent Information
- Application Number
- CN201980065064.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-10
- Filing Date
- 2019-08-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-08-20
AI Technical Summary
Existing PI4K inhibitors have safety issues and the effects on CYP3A4 in drug metabolism in the treatment of virus-induced diseases, resulting in an increased risk of drug-drug interactions and an insufficient impact on the autophagy process.
A new class of compounds, formula (I), has high antiviral activity and low CYP3A4 inhibitory activity, is developed for the treatment of viral infections and diseases associated with autophagy, by adjusting the autophagy process to improve cellular function.
It significantly reduces the risk of drug-drug interactions, improves therapeutic effects, and improves cellular health by regulating the autophagy process, providing effective treatment options for a variety of viral infections and autophagy-related diseases.
Smart Images

Figure CN112969703B_ABST
Abstract
Description
Technical Field
[0001] The present invention generally relates to compounds having usefulness in therapy, particularly in the treatment of conditions caused by certain viruses, such as the common cold, encephalitis, meningitis, myocarditis, conjunctivitis, pancreatitis, as well as diabetes, cancer and neurodegenerative diseases (e.g., Alzheimer's disease and amyotrophic lateral sclerosis). More particularly, the present invention relates to certain amino-substituted heteroaromatic compounds and their use in therapy. Background Art
[0002] Pyrazolo[1,5-a]pyrimidine is a commonly used scaffold in medicinal chemistry, and its derivatives are known to have potential as analgesics, benzodiazepines, Receptor antagonists, angiotensin II receptor antagonists, angiogenesis inhibitors, anti-inflammatory agents, neuropeptide Y receptor antagonists, COX2-inhibitors and corticotropin-releasing hormone receptor type 1 antagonists, as well as effective CHK1 inhibitors (e.g. Mayo et al. (Adv. Synth. Catal. 2003, 345, 620-624; Tellew et al. (Bioorg. Med. Chem. Lett. 2010, 20, 7259-7264); Chen et al. (Bioorg. Med. Chem. Lett. 2011, 20, 7264); Chen et al. (Bioorg. Med. Chem. Lett. 2013, 21, 7270-7271); Chen et al. (Bioorg. Med. Chem. Lett. 2014, 21, 7280-7291); Chen et al. (Bioorg. Med. Chem. Lett. 2015, 21, 7290-7291); Chen et al. (Bioorg. Med. Chem. Lett. 2013, 21, 7280-7291); Chen et al. (Bioorg. Med. Chem. Lett. 2014 ... m.Lett.2004,14,3669-3673); Labroli et al. (Bioorg.Med.Chem.Lett.2011,21,471-474); Griffith et al. (Bioorg.Med.Chem.Lett.2011,21,2641-2645); Gilligan et al. (J.Med.Chem.2009,52,3073-3083); He et al. (U.S. Pat. No. 6,313,124B1); and Wren et al. (WO 2010 / 086040).
[0003] This backbone has also been described in phosphatidylinositol 4-kinase (PI4K) inhibitors. Bianco et al. (PLoS Pathogens, 2012, 8(3), 1-17) and LaMarche et al. (Antimicr. Agents and Chemother. 2012, 56(10), 5149-5156) have shown that PI4K is important for hepatitis C virus (HCV) replication, and Yang et al. (J. Biol. Chem. 2012, 287(11), 8547-8467) have shown that it is the same for coronaviruses. McLeod et al. (ACS Med. Chem. Lett. 2013, 4(7), 585-589) and van der Schaar et al. (Antimicrobial Agents Chemother. 2013, 57(10), 4971-4981) have shown that some imidazopyrazine derivatives that inhibit PI4K are effective antiviral agents against picornaviruses.
[0004] Gudmundsson et al. (Bioorg. Med. Chem. Lett. 2009, 19, 5689-5692) have disclosed some 3-arylpyrazolo[1,5-a]pyrimidines having potent activity against herpes viruses.
[0005] Hwang et al. (Bioorg. Med. Chem. Lett. 2012, 22, 7297-7301) have described 3-arylpyrazolo[1,5-a]pyrimidines as PI4K inhibitors with anti-HCV effects. Décor et al. (Bioorg Med Chem Lett. 2013, 23, 3841-7) have also shown that PI4K is important for enterovirus replication. However, they have also shown that when tested in vivo, PI4K inhibitors (non-3-arylpyrazolo[1,5-a]pyrimidines and 3-arylpyrazolo[1,5-a]pyrimidine 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidin-7-amine (called T-00127-HEV1)) induced death in mice, which raises doubts about the safety of inhibiting PI4K.
[0006] In WO 2015 / 110491, certain 3-arylpyrazolo[1,5-a]pyrimidines are described as PI4K inhibitors for use in the treatment of virus-induced diseases.
[0007] Imidazolo[1,2-b]pyridazine derivatives have been described as Mps1 kinase inhibitors (Kusakabe, J. Med. Chem. 2015, 58, 1760-1775). Similar backbones have been described in phosphatidylinositol 4-kinase (PI4K) inhibitors (McLeod et al. (ACS Med. Chem. Lett. 2013, 4(7), 585-589) and van der Schaar et al. (Antimicrobial Agents Chemother. 2013, 57(10), 4971-4981), and inhibitors of PI4K have been shown to be effective antiviral agents (Bianco et al., PLoS Pathogens, 2012, 8(3), 1-17; LaMarche et al., Antimicr. Agents and Chemother. 2012, 56(10), 5149-5156; Decor et al., Bioorg. Med. Chem. Lett. 2013, 23, 3841-7).
[0008] Autophagy is a homeostatic degradation process in cells that is used to produce nutrients during stress and as a mechanism to recycle damaged organelles or microorganisms in the cytosol (Karanasios et al., 2016, Autophagy at the cell, tissue and organismal level (Springer)). Many pathogens interact with the host autophagy pathway and may impair normal autophagy. Lai et al. (Virus, 2016, 8(32), 1-13) described that viruses disrupt the autophagy mechanism to facilitate viral replication and exit from the host, and that inhibition of PI4KIIIβ will have an impact on the autophagy process and thus inhibit viral replication. Sridhar et al. (EMBO J. 2013, 32, 324-339) described that PI4KIIIβ is a key factor in autophagy, and believed that many diseases are caused by or related to impaired or abnormal autophagy, such as neurodegenerative and neuropsychiatric diseases, cancer, heart disease, inflammatory diseases and diabetes (Polajnar et al., J. Cell. Mol. Med. 2014, 9(18). 1705-1711; Levine et al., Cell, 2008, 132(1), 27-42; Barlow, et al., DNA Cell. Biol, 2015, 34(4), 252-260).
[0009] Cytochrome P450 3A4 (abbreviated as CYP3A4) is one of the most important cytochrome P450 enzymes and is involved in the oxidative biotransformation of many clinically useful therapeutic agents. Therefore, inhibitors of CYP3A4 can affect the metabolism of a variety of drugs, increase their bioavailability, and thus cause adverse events due to unexpectedly high drug exposure. In patients who receive several different drugs in parallel, such drug-drug interactions must be avoided, and this sometimes excludes the use of some drugs that are otherwise therapeutically useful.
[0010] Therefore, there is a continuing need for new drugs that not only possess the sought post-therapeutic activity but also have little or no effect on the activity of enzymes involved in drug metabolism, particularly CYP3A4. Summary of the invention
[0011] The first aspect is a compound of formula (I)
[0012]
[0013] or a pharmaceutically acceptable salt thereof, wherein
[0014] One of X and Y is C and the other is N;
[0015] R1 is selected from halogen, CN, NH(CH3), N(CH3)2, C1-C4 alkoxy optionally substituted by 1-3 halogens, and C1-C4 alkyl, wherein the C1-C4 alkyl is optionally substituted by 1-3 halogens, CN, NH(CH3) or N(CH3)2; and R2 is 3,4-dimethoxyphenyl or 1,3-dimethyl-1H-indazol-5-yl.
[0016] The compounds of formula (I) combine high antiviral activity with low (preferably substantially negligible) CYP3A4 inhibitory activity. Thus, provided herein are drugs with a significantly reduced risk of drug-drug interactions.
[0017] Another aspect is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in therapy.
[0018] Another aspect is a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable excipient.
[0019] Another aspect is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating a viral infection (eg an RNA viral infection).
[0020] Another aspect is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a viral infection (eg an RNA viral infection).
[0021] Another aspect is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of the diseases mentioned herein, which is capable of improving impaired or dysregulated autophagy in cells.
[0022] Another aspect is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating a disease associated with impaired or aberrant autophagy.
[0023] Another aspect is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating a disease associated with impaired autophagy.
[0024] Another aspect is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating a disease associated with abnormal autophagy.
[0025] Another aspect is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating a non-enveloped single-stranded (+) RNA viral infection.
[0026] Another aspect is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating an enteroviral infection (eg a picornavirus infection).
[0027] On the other hand, a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating the following diseases, wherein the diseases are selected from: pancreatitis, poliomyelitis, encephalitis, meningitis, sepsis, cancer (e.g., breast cancer, prostate cancer, ovarian cancer or colorectal cancer), paralysis, heart disease (e.g., myocarditis), diabetes, colds, hand, foot and mouth disease, herpangina, pleurisy, diarrhea, mucocutaneous lesions, respiratory diseases, conjunctivitis, myositis, chronic fatigue syndrome, neuropsychiatric diseases and neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease) or inflammatory conditions.
[0028] Another aspect is a method for treating a viral infection (eg, an RNA viral infection) by administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION
[0029] Unless otherwise defined or clearly indicated by the context, all technical and scientific terms and abbreviations used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. However, the definitions of some terms used herein will be given below.
[0030] "Pharmaceutically acceptable" means useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes acceptable for veterinary as well as human pharmaceutical use.
[0031] The term "treating" (or "treatment") of a disease or condition can refer to ameliorating the disease or condition (i.e., arresting or reducing the development of the disease or at least one clinical symptom thereof), and / or improving at least one physical parameter that may not be discernible by the patient. The term can also refer to inhibiting the disease or condition, either physically (e.g., stabilizing discernible symptoms), physiologically (e.g., stabilizing a physical parameter), or both.
[0032] "Therapeutically effective amount" refers to the amount of a compound that, when administered to a patient for treating a disease, is sufficient to effect such treatment of the disease."Therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the patient to be treated.
[0033] "Viral infection" refers to an infection in a mammal by a virus.
[0034] "RNA viral infection" refers to a viral infection in which the virus has RNA (ribonucleic acid) as its genetic material.
[0035] "Non-enveloped single-stranded (+) RNA virus infection" refers to infection by a non-enveloped single-stranded (+) RNA virus.
[0036] A "non-enveloped virus" is a virus that lacks a viral envelope.
[0037] A "single-stranded (+) RNA virus" is a virus that has its genetic material as single-stranded RNA, and this RNA can be immediately translated into viral proteins by a cell infected with the virus.
[0038] "Abnormal autophagy" refers to, for example, autophagy that favors viral replication and release.
[0039] "Impaired autophagy" refers to autophagy that functions less than normal in a cell.
[0040] Diseases associated with impaired or aberrant autophagy that can be treated according to the invention can for example be selected from neurodegenerative and neuropsychiatric diseases, cancer, heart disease, inflammatory diseases and diabetes, such as the diseases mentioned herein.
[0041] The term "mammal" refers to a human or any mammal, such as a primate, a farm animal, a pet animal, or a laboratory animal. Examples of such animals are monkeys, cows, sheep, goats, horses, pigs, dogs, cats, rabbits, mice, rats, etc. Preferably, the mammal is a human. However. In some embodiments, the mammal is an animal, such as a farm animal, such as a cow, sheep, goat, horse, or pig. In some other embodiments, the animal is a pet, such as a dog, cat, or rabbit.
[0042] The term "excipient" refers to a pharmaceutically acceptable chemical, such as a chemical known to those of ordinary skill in the pharmaceutical arts that aids in the administration of a medicament. It is a compound that can be used to prepare a pharmaceutical composition, is generally safe, non-toxic, and is not biologically or otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. Exemplary excipients include binders, surfactants, diluents, disintegrants, antiadherents, and lubricants.
[0043] Unless otherwise stated or obvious from the context, the term "halogen" refers to F (fluorine), Cl (chlorine), Br (bromine) or I (iodine).
[0044] Unless otherwise indicated or apparent from the context, the term "Cm-Cn alkyl" means a straight or branched chain alkyl group having m to n carbon atoms. For example, the term "C1-C4 alkyl" means a straight or branched chain alkyl group having 1 to 4 carbon atoms. Such C1-C4 alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
[0045] The term "Cm-Cn alkoxy" refers to a moiety of the formula
[0046]
[0047] wherein R is a Cm-Cn alkyl group.
[0048] The term NH(CH3) denotes a moiety of the formula
[0049]
[0050] The term N(CH3)2 denotes a moiety of the formula
[0051]
[0052] The term CN denotes a moiety of the formula
[0053]
[0054] In the compound of formula (I), one of X and Y is C and the other is N. In some embodiments, X is C and Y is N, that is, the compound represented by formula (Ia)
[0055]
[0056] wherein R1 and R2 are as defined herein.
[0057] In some embodiments, X is N and Y is C, that is, the compound represented by formula (Ib)
[0058]
[0059] wherein R1 and R2 are as defined herein.
[0060] In the compounds of formula (I), R1 is selected from halogen, CN, NH(CH3), N(CH3)2, C1-C4 alkoxy optionally substituted by 1-3 halogens and C1-C4 alkyl optionally substituted by 1-3 halogens, CN, NH(CH3) or N(CH3)2.
[0061] In some embodiments, R1 is selected from halogen, CN, C1-C4 alkoxy optionally substituted with 1-3 halogens, and C1-C4 alkyl optionally substituted with 1-3 halogens.
[0062] In some embodiments, when R1 is halogen, the halogen is selected from F, Cl and Br. In some embodiments, the halogen is F or Cl. In some embodiments, the halogen is F.
[0063] In some embodiments, when R1 is an optionally substituted C1-C4 alkyl, the alkyl is more particularly a C1-C3 alkyl. In some embodiments, the alkyl is methyl or ethyl. In some embodiments, the alkyl is methyl. In some embodiments, the alkyl is ethyl.
[0064] In some embodiments, when R1 is an optionally substituted C1-C4 alkyl, the alkyl is unsubstituted. In some other embodiments, the alkyl is substituted with 1-3 halogens, CN, NH(CH3) or N(CH3)2. In some embodiments, when the alkyl is substituted with 1-3 halogens, the halogen is selected from F and Cl, particularly F. In some embodiments, the alkyl is substituted with 1-3 halogens and / or is substituted with a substituent selected from CN, NH(CH3) and N(CH3)2.
[0065] In some embodiments, when R1 is substituted alkyl, any substituent on the alkyl is selected from halogen and CN. In some other embodiments, when R1 is substituted alkyl, any substituent on the alkyl is selected from halogen, NH(CH3) and N(CH3)2. In some other embodiments, when R1 is substituted alkyl, any substituent on the alkyl is selected from NH(CH3) and N(CH3)2. In some other embodiments, when R1 is substituted alkyl, any substituent on the alkyl is selected from halogen, such as F and Cl, especially F.
[0066] In some embodiments, when R1 is C1-C4 alkoxy, the alkoxy is more particularly C1-C3 alkoxy. In some embodiments, the alkoxy is C1-C2 alkoxy. In some embodiments, the alkoxy is methoxy. In some embodiments, when R1 is an optionally substituted C1-C4 alkoxy, the alkoxy is unsubstituted. In some other embodiments, the alkoxy is substituted by 1-3 halogens. In some embodiments, when the alkoxy is substituted by 1-3 halogens, any such halogen is selected from F and Cl, particularly F.
[0067] In some embodiments, R1 is selected from halogen, CN, optionally substituted C1-C4 alkoxy and optionally substituted C1-C4 alkyl. In some of these embodiments, R1 is selected from halogen, optionally substituted C1-C3 alkoxy and optionally substituted C1-C3 alkyl, for example, selected from F, Cl, CN, optionally substituted C1-C3 alkoxy and optionally substituted C1-C3 alkyl; or selected from F, Cl, CN, optionally substituted methoxy and optionally substituted methyl and ethyl; or selected from F and optionally substituted methyl. In some of these embodiments. Any substituent on any alkyl or alkoxy is F or Cl, particularly F. In other of these embodiments, R1 is selected from halogen, unsubstituted C1-C4 alkoxy and unsubstituted C1-C4 alkyl, for example, selected from F, Cl, CN, C1-C3 alkoxy and C1-C3 alkyl; or selected from F, Cl, CN, methoxy, methyl and ethyl; or selected from F and methyl.
[0068] In some embodiments, R1 is selected from halogen and optionally substituted C1-C4 alkyl. In some of these embodiments, R1 is selected from halogen and optionally substituted C1-C3 alkyl, for example selected from F, Cl and optionally substituted C1-C3 alkyl; or selected from F, Cl and optionally substituted methyl or ethyl; or selected from F and optionally substituted methyl or ethyl; or selected from F and optionally substituted methyl. In some of these embodiments, any substituent on the alkyl is F or Cl, in particular F. In other of these embodiments, R1 is selected from halogen and unsubstituted C1-C4 alkyl, for example selected from F, Cl and C1-C3 alkyl; or selected from F, Cl, methyl and ethyl; or selected from F, methyl and ethyl; or selected from F and methyl.
[0069] In some other embodiments, R1 is selected from halogen, unsubstituted C1-C4 alkyl and unsubstituted C1-C4 alkoxy, for example, selected from F, Cl, C1-C3 alkyl and C1-C3 alkoxy; or selected from F, Cl, methyl, ethyl and methoxy; or selected from F, methyl, ethyl and methoxy; or selected from F, methyl and methoxy; or selected from methyl and methoxy.
[0070] In some embodiments, R1 is selected from optionally substituted C1-C4 alkyl and optionally substituted C1-C4 alkoxy. In some embodiments, R1 is selected from unsubstituted C1-C4 alkyl and unsubstituted C1-C4 alkoxy. In other embodiments, R1 is selected from optionally substituted C1-C4 alkyl and unsubstituted C1-C4 alkoxy. In other embodiments, R1 is selected from C1-C4 alkyl and C1-C4 alkoxy, and the alkoxy and alkyl are optionally substituted by 1-3 halogen (for example 1-3 halogens selected from F and Cl, particularly 1-3 F). In some embodiments, R1 is selected from methyl, ethyl, trifluoromethyl and methoxy.
[0071] In yet other embodiments, R1 is selected from halogen, for example R1 is F or Cl, especially F.
[0072] In still other embodiments, R1 is selected from F, CN, methoxy, methyl, trifluoromethyl, and ethyl; for example, selected from F, methyl, trifluoromethyl, and ethyl.
[0073] In the compound of formula (I), R2 is 3,4-dimethoxyphenyl or 1,3-dimethyl-1H-indazol-5-yl, that is, R2 is a part of formula (II) or (III)
[0074]
[0075] In some embodiments, R2 is 3,4-dimethoxyphenyl, a moiety of formula (II), and the compounds provided herein can be represented by formula (Ic)
[0076]
[0077] wherein X, Y and R1 are as defined herein.
[0078] In some other embodiments, R2 is 1,3-dimethyl-1H-indazol-5-yl, a moiety of formula (III), and the compounds provided herein can be represented by formula (Id)
[0079]
[0080] wherein X, Y and R1 are as defined herein.
[0081] In some embodiments of the compound of formula (Ic), X is C and Y is N, that is, the compound can be represented by formula (Ie)
[0082]
[0083] wherein R1 is as defined herein.
[0084] In some other embodiments of the compound of formula (Ic), X is N and Y is C, that is, the compound can be represented by formula (If)
[0085]
[0086] wherein R1 is as defined herein.
[0087] In some embodiments of the compound of formula (Id), X is C and Y is N, that is, the compound can be represented by formula (Ig)
[0088]
[0089] wherein R1 is as defined herein.
[0090] In some other embodiments of the compound of formula (Id), X is N and Y is C, that is, the compound can be represented by formula (Ih)
[0091]
[0092] wherein R1 is as defined herein.
[0093] Unless otherwise stated or apparent from the context, any reference to a compound of formula (I) should also be construed as a reference to a compound represented by any of formulas (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) and (Ih).
[0094] In some embodiments, the compound of formula (I) is more particularly a compound of formula (Ie) or (Ih), that is, a compound of formula (I)
[0095]
[0096] or a pharmaceutically acceptable salt thereof, wherein
[0097] R1 is as defined herein; and
[0098] X is C, Y is N, and R2 is 3,4-dimethoxyphenyl; or
[0099] X is N, Y is C, and R2 is 21,3-dimethyl-1H-indazol-5-yl.
[0100] The compound of formula (I) can also be converted into a suitable pharmaceutically acceptable salt. The term pharmaceutically acceptable salt of a compound refers to a pharmaceutically acceptable salt as defined herein, and it has the desired pharmacological activity of the parent compound. Pharmaceutically acceptable salts include acid addition salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; or acid addition salts formed with organic acids, such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, p-toluenesulfonic acid, trimethylacetic acid, etc.
[0101] In the preparation of acid addition salts, it is preferred to use an acid that forms a suitable therapeutically acceptable salt. Examples of such acids are hydrohalic acids, sulfuric acid, phosphoric acid, nitric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxylic acids or sulfonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybenzoic acid, pamoic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, halogen benzenesulfonic acid, toluenesulfonic acid or naphthalenesulfonic acid.
[0102] When a chiral atom is present in a chemical structure, unless otherwise specified, it is intended that all stereoisomers associated with the chiral atom are encompassed in the structure. Using the Cahn-Ingold-Prelog RS notation system, any asymmetric atom may exist in (R)- or (S)-configuration, and the compound may exist as a mixture of its stereoisomers, such as a racemic mixture, or as only one stereoisomer, each within the scope of the present invention.
[0103] The present invention includes pharmaceutical compositions comprising a compound of formula (I) or an individual isomer, a racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable excipient (e.g., a carrier) and optionally other therapeutic and / or prophylactic ingredients.
[0104] The present invention includes pharmaceutical compositions comprising at least one compound of formula (I) or an individual isomer, a racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable excipient (e.g., a carrier) and optionally other therapeutic and / or prophylactic ingredients.
[0105] The pharmaceutical composition according to the present invention can be used for local (local) or systemic administration, for example, for enteral administration, such as rectal or oral administration, or for parenteral administration to mammals (especially humans), and comprises a therapeutically effective amount of a compound according to the present invention or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier). The therapeutically effective amount of the active ingredient is as defined above, and depends on, for example, the species, body weight, age, individual condition, individual pharmacokinetic data, disease to be treated, and mode of administration of the mammal.
[0106] For enteral (e.g. oral) administration, the compounds of the present invention can be formulated into various dosage forms. Pharmaceutical compositions and dosage forms can contain one or more compounds of the present invention or one or more pharmaceutically acceptable salts thereof as active ingredients. Pharmaceutically acceptable carriers can be solid or liquid. Preparations in solid form include powders, tablets, pills, lozenges, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which can also serve as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, preservative, tablet disintegrant, or encapsulating material. In powders, the carrier is typically a finely divided solid, which is a mixture with the finely divided active ingredient. In tablets, the active ingredient is typically mixed with a carrier having the necessary binding capacity in a suitable ratio and pressed into a desired shape and size. Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting point wax, cocoa butter, and the like. The formulation of the active compound may include encapsulating material as a carrier, providing a capsule in which the active component (with or without carriers) is surrounded by a carrier which is in combination with it.
[0107] Other forms suitable for oral administration include liquid form preparations (including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions) or solid form preparations (intended to be converted into liquid form preparations shortly before use). Emulsions can be prepared in solution, for example in aqueous propylene glycol solution, or can contain emulsifiers, such as lecithin, sorbitan monooleate or gum arabic. Aqueous solutions can be prepared by dissolving the active ingredient in water and adding suitable colorants, flavorings, stabilizers and thickeners. Aqueous suspensions can be prepared by dispersing the finely divided active ingredient in water with a viscous substance, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose and other known suspending agents. Solid form preparations include solutions, suspensions and emulsions, and in addition to the active ingredient, can also contain colorants, flavorings, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizers, etc.
[0108] Exemplary compositions for rectal administration include suppositories, which may contain, for example, suitable non-irritating excipients such as cocoa butter, synthetic glycerides or polyethylene glycols which are solid at ordinary temperatures but liquefy and / or dissolve in the rectal cavity to release the drug.
[0109] The compounds of the invention may also be administered parenterally, for example by inhalation, injection or infusion, for example by intravenous, intraarterial, intraosseous, intramuscular, intracerebral, intracerebroventricular, intrasynovial, intrasternal, intrathecal, intralesional, intracranial, intradermal and subcutaneous injection or infusion.
[0110] Therefore, for parenteral administration, the pharmaceutical composition of the present invention can be in the form of a sterile injectable or infusible preparation, for example as a sterile aqueous or oily suspension. The suspension can be prepared using a suitable dispersant or wetting agent (e.g., Tween 80) and a suspending agent according to techniques known in the art. The sterile injectable or infusible preparation can also be a sterile injectable or infusible solution or suspension in a nontoxic parenterally acceptable diluent or solvent. For example, the pharmaceutical composition can be a solution in 1,3-butanediol. Other examples of acceptable vehicles and solvents that can be used for the composition of the present invention include, but are not limited to, mannitol, water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, non-volatile oils are generally used as solvents or suspension media. For this purpose, any mild non-volatile oil can be used, including synthetic monoglycerides or diglycerides. Fatty acids (e.g., oleic acid) and their glyceride derivatives can be used to prepare injectables, as natural pharmaceutically acceptable oils (e.g., olive oil or castor oil), especially their polyoxyethylated forms. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant.
[0111] Solutions for parenteral use may also contain suitable stabilizers and, if desired, buffer substances. Suitable stabilizers include antioxidants such as sodium bisulfate, sodium sulfite or ascorbic acid (alone or in combination), citric acid and its salts and sodium EDTA. Parenteral solutions may also contain preservatives such as benzalkonium chloride, methyl or propyl parahydroxybenzoate and chlorobutanol.
[0112] For inhalation or nasal administration, suitable pharmaceutical formulations are particles, aerosols, powders, mists or droplets, for example, with an average size of about 10 μm in diameter or less. For example, the composition for inhalation can be prepared as a saline solution, using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons and / or other solubilizing agents or dispersants known in the art.
[0113] In some embodiments, the formulation of the present invention is a liposome formulation. Liposomal formulations are well known in the pharmaceutical field and are described, for example, in Remington, Essentials of Pharmaceutics, Ed. Linda Felton (Pharmaceutical Press 2012), pages 456-7 and many other publications. Information on the selection of, for example, suitable liposome formulations, suitable lipids, preparation methods, etc. is readily available to those of ordinary skill in the art. Examples of lipids for liposome formation are phospholipids, sphingolipids, sterol lipids, and fatty acids. Lipids suitable for liposome formation can be selected from, for example, Purchased by Polar Lipids, Inc.
[0114] The pharmaceutical compositions of the present invention may also be administered topically to the skin or mucosa. For topical administration, the pharmaceutical composition may be, for example, a lotion, a gel, a paste, a tincture, a transdermal patch, or a gel for transmucosal delivery.
[0115] The composition can be formulated into a suitable ointment containing the active component suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
[0116] Alternatively, the pharmaceutical composition may be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0117] The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation.
[0118] Suitable pharmaceutical excipients (eg, carriers) and methods for preparing pharmaceutical dosage forms are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in the field of pharmaceutical formulations.
[0119] The pharmaceutical composition may comprise from about 1% to about 95%, preferably from about 20% to about 90% of the compound of formula (I), and at least one pharmaceutically acceptable excipient. Typically, the compound of the present invention will be administered in a therapeutically effective amount by any acceptable mode of administration of a medicament for similar purposes. Suitable daily doses are typically within the range of 1-1000 mg, such as 1-500 mg per day, or 1-50 mg per day, depending on many factors, such as the severity of the disease to be treated, the age and relative health of the patient, the efficacy of the compound used, the route of administration and form, and the indications involved in administration, etc. Those of ordinary skill in the art of treating such diseases will be able to determine the therapeutically effective amount of the compound of the present invention for a given disease without excessive experimentation and relying on personal knowledge and the disclosure of the present application. The compound of the present invention can be administered in the form of a pharmaceutical preparation, including those suitable for enteral or parenteral administration. The preferred mode of administration is typically oral administration using a convenient daily dosage regimen, which can be adjusted according to the degree of pain.
[0120] The compounds of the present invention are expected to be useful for treating diseases caused by RNA virus infection (eg, non-enveloped single-stranded (+) RNA virus infection), particularly diseases caused by picornaviruses, in mammals.
[0121] The picornavirus can be, for example, a Parechovirus (e.g., Ljungan or Parecho), a cardiovirus (e.g., EMCV or Theile's virus), an enterovirus (e.g., EV, coxsackievirus, poliovirus, rhinovirus), or a hepatovirus. For veterinary use, the picornavirus can be, for example, a foot-and-mouth disease virus or a porcine enterovirus.
[0122] Diseases believed to be associated with, caused by or otherwise related to viral infections (e.g., picornavirus infections) are, for example, neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease), poliomyelitis, encephalitis, meningitis, sepsis, cancer, paralysis, myocarditis, diabetes, colds, hand, foot and mouth disease, herpangina, pleurisy, diarrhea, mucocutaneous lesions, respiratory diseases, conjunctivitis, myositis and chronic fatigue syndrome.
[0123] The synthesis and identification of compounds of formula (I) defined herein are considered to be well known to those skilled in the art by the methods generally described in the following non-limiting examples and in the literature (e.g., PCT / EP2018 / 058522 (published as WO 2018 / 185120A1) and PCT / EP2015 / 051177 (published as WO 2015 / 110491A2), the contents of which are incorporated herein by reference.
[0124] Example
[0125] General Procedure
[0126] Unless otherwise stated, the reaction was carried out in a flame-dried sealed tube or oven-dried glassware under a positive pressure of argon or nitrogen. Air and moisture sensitive liquids and solutions were transferred by syringe. Tetrahydrofuran (THF) was distilled from sodium / benzophenone-ketyl. Dichloromethane (CH2Cl2) was distilled from calcium hydride. All other chemicals were obtained from commercial suppliers and used without further purification unless otherwise stated. The molecular sieves were activated at 350°C and crushed just before use, then flame dried under vacuum. The reaction was monitored by thin layer chromatography (TLC) using 0.25mm E.Merck pre-coated silica gel plates. The organic solution was concentrated by rotary evaporation below 50°C. Rapid column chromatography was performed using 60-120, 230-400 mesh silica gel and neutral alumina. Unless otherwise stated, the product refers to chromatographic and spectrally pure compounds.
[0127] instrument
[0128] 1 H and 13 C spectra were recorded on a Bruker AVANCE III HD 400MHz spectrometer or a Bruker AVANCE II 300MHz spectrometer. Chemical shifts are expressed in parts per million (δ scale) downfield from tetramethylsilane and referenced to residual resonances in the NMR solvent (CHCl3: 7.26 for 1H NMR δ and 77.16 for 13C NMR δ). LC-MS was performed on an Agilent XCT Ion Trap equipped with a chemical workstation and Bruker daltonics software.
[0129] Synthesis of 3-(3,4-dimethoxyphenyl)-8-iodo-2,6-dimethylimidazo[1,2-b]pyridazine The synthetic intermediate 3-(3,4-dimethoxyphenyl)-8-iodo-2,6-dimethylimidazo[1,2-b]pyridazine was synthesized by the following multi-step method: Step 1: 2,6-dimethylimidazo[1,2-b]pyridazine
[0130] Chloroacetone (58 mL, 683 mmol) was added to a stirred solution of 6-methylpyridazine-3-ylamine (50 g, 455.3 mmol) in ethanol (500 mL), and the solution was heated at 85 ° C for 10 hours. After completion, the ethanol in the reaction was distilled out. The obtained crude product was purified by flash column chromatography (neutral alumina) and the desired compound 2,6-dimethylimidazo[1,2-b]pyridazine (36 g, 53.4%) was eluted with 10% ethyl acetate-hexane as a dark brown solid.
[0131] Step 2: 3-Bromo-2,6-dimethylimidazo[1,2-b]pyridazine To a stirred solution of 2,6-dimethylimidazo[1,2-b]pyridazine (36 g, 244.5 mmol) in acetonitrile (360 mL) was added N-bromosuccinimide (NBS) (52.2 g, 293.4 mmol) and stirred at ambient temperature for 1 hour. After completion, the acetonitrile in the reaction was distilled off. The crude product obtained was purified by flash column chromatography (neutral alumina) and the desired compound 3-bromo-2,6-dimethylimidazo[1,2-b]pyridazine (18 g, 32.5%) was eluted with 15% ethyl acetate-hexane as a solid.
[0132] Step 3: 3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazine
[0133] In a 100 ml round bottom flask were added 3-bromo-2,6-dimethylimidazo[1,2-b]pyridazine (5 g, 17.6 mmol), borate (4.4 g, 19.4 mmol), potassium carbonate (7.5 g, 54.3 mmol) and dioxane:water (45 ml:5 ml). The solution was degassed with N2 for 10 minutes and then [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (Pd(dppf)Cl2.DCM complex) (1.8 g, 2.2 mmol) was added. The reaction was heated at 100 °C for 16 hours. Upon completion, the reaction was diluted with ethyl acetate and filtered through a celite bed. The filtrate was partitioned between ethyl acetate and water. The ethyl acetate layer was dried over Na2SO4 and concentrated under reduced pressure. The crude product obtained was purified by flash column chromatography (neutral alumina) using 30% ethyl acetate-hexane to elute the desired compound 3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazine (4.2 g, 67.7%) as an off-white solid.
[0134] Step 4: 3-(3,4-dimethoxyphenyl)-8-iodo-2,6-dimethylimidazo[1,2-b]pyridazine
[0135] At -78 ° C, a solution of 3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazine (0.2 g, 0.705 mmol) dissolved in THF (5 mL) was added dropwise to a stirred solution of 2M lithium diisopropylamide (LDA) (0.7 ml, 1.4 mmol) in THF. After 10 minutes, iodine (0.178 g, 0.705 mmol) dissolved in THF (3 mL) was added, and the reaction was stirred at ambient temperature for 1 hour. After completion, the reaction was quenched with saturated NH4Cl solution and extracted with ethyl acetate. The ethyl acetate layer was dried under Na2SO4 and concentrated under reduced pressure. The crude product obtained was purified by flash column chromatography (neutral alumina) and the desired compound 3-(3,4-dimethoxyphenyl)-8-iodo-2,6-dimethylimidazo[1,2-b]pyridazine (30 mg, 10.7%) was eluted with 30% ethyl acetate-hexane as a light yellow solid.
[0136] Example 1
[0137] 3-(3,4-Dimethoxyphenyl)-2,6-dimethyl-N-((2-methylpyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine
[0138]
[0139] To a stirred solution of 3-(3,4-dimethoxyphenyl)-8-iodo-2,6-dimethylimidazo[1,2-b]pyridazine (0.1 g, 0.240 mmol) and amine (0.06 g, 0.312 mmol) in toluene (2 mL) was added cesium carbonate (0.156 g, 0.48 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) (7 mg, 0.012 mmol) and Pd(OAc)2 (2 mg, 0.012 mmol). The reaction was stirred at 105 ° C for 16 hours. After completion, the reaction was diluted with 10% MeOH-CH2Cl2 and filtered through a diatomaceous earth bed. The filtrate was concentrated and the solid obtained was washed with acetonitrile to obtain Example 2 (0.09 g, 91.83%) as a light brown solid.
[0140] Example 2
[0141] 3-(3,4-Dimethoxyphenyl)-N-((2-fluoropyridin-4-yl)methyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-amine
[0142]
[0143] To a stirred solution of 3-(3,4-dimethoxyphenyl)-8-iodo-2,6-dimethylimidazo[1,2-b]pyridazine (0.15 g, 0.360 mmol) and amine (0.093 g, 0.46 mmol) in toluene (3 mL) was added cesium carbonate (0.23 g, 0.72 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) (11 mg, 0.018 mmol) and Pd(OAc)2 (4 mg, 0.018 mmol). The reaction was stirred at 105 °C for 16 hours. After completion, the reaction was diluted with 10% MeOH-CH2Cl2 and filtered through a diatomaceous earth bed. The filtrate was concentrated and the solid obtained was washed with acetonitrile to give Example 1 (0.120 g, 80%) as a light brown solid.
[0144] Synthesis of 7-chloro-3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidine
[0145] The synthetic intermediate 7-chloro-3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidine was synthesized by the following multi-step method:
[0146] Step 1: 2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ol
[0147] 3-Amino-5-methylpyrazole (100 g, 1.02 mol), ethyl acetoacetate (161 mL, 1.23 mol), acetic acid (300 mL) and 1,4-dioxane (1000 mL) were added to a round-bottom flask. The reaction was refluxed at 105 ° C for 16 hours. An off-white solid was obtained after the reaction was completed and filtered by suction. The solid was washed with cold hexane and dried in vacuo to obtain 2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ol (85 g, 49%) as an off-white solid.
[0148] Step 2: 7-Chloro-2,5-dimethylpyrazolo[1,5-a]pyrimidine To a solution of 2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ol (120 g, 0.73 mol) in acetonitrile (1200 mL) was added POCl3 (103 mL, 1.1 mol) dropwise. After the addition was complete, the reaction was heated at 80°C for 12 hours. After completion, the POCl3 in the reaction was distilled off. The crude product was diluted with water, neutralized with saturated NaHCO3 solution, and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography, eluting 7-chloro-2,5-dimethylpyrazolo[1,5-a]pyrimidine with 20% ethyl acetate-hexane as an off-white solid (108 g, 80.8%).
[0149] Step 3: 7-Chloro-3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidine
[0150] N-iodosuccinimide (163.5 g, 0.726 mol) was added in portions to an ice-cold solution of 7-chloro-2,5-dimethylpyrazolo[1,5-a]pyrimidine (120 g, 0.66 mol) in acetonitrile (1200 mL) at -10 ° C. The reaction was stirred at this temperature for 1 hour. After completion, a solid was observed. The reaction was quenched with ice-cold water and filtered by suction. The obtained solid was washed with hexane and dried in vacuo to give 7-chloro-3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidine as a white solid (182.8 g, 89.9%).
[0151] Synthesis of 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole Boronic ester 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole was synthesized by the following multi-step method:
[0152] Step 1: 5-Bromo-1,3-dimethyl-1H-indazole
[0153] A stirred solution of 1-(5-bromo-2-fluorophenyl)ethanone (50 g, 230 mmol) and N-methylhydrazine (42.4 mL, 805 mmol) in pyridine (500 mL) was heated at 90 ° C for 10 hours. After completion, the pyridine in the reaction was distilled out. The crude product was distributed between water and ethyl acetate. The ethyl acetate layer was dried over sodium sulfate and concentrated. The obtained crude product was purified by flash column chromatography (neutral alumina) and the desired compound 5-bromo-1,3-dimethyl-1H-indazole (20.23 g, 41.8%) was eluted with 2% ethyl acetate-hexane as a light brown viscous compound.
[0154] Step 2: 1,3-Dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole To a solution of 5-bromo-1,3-dimethyl-1H-indazole (26 g, 115 mmol) and bispinacolatodiboron (32.3 g, 127 mmol) in 1,4-dioxane (260 mL) was added KOAc (34 g, 345 mmol). The reaction was degassed with N2 for 10 min, then Pd(PPh3)4 (6.6 g, 5.57 mmol) was added and heated at 95°C for 16 h. After the addition was complete, the reaction was heated at 80°C for 12 h. After completion, the reaction was filtered through celite and the filtrate was concentrated. The crude product was purified by flash column chromatography (neutral alumina) and eluted with 5% ethyl acetate-hexane to obtain the desired compound 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (18 g, 52.1%) as an off-white solid compound.
[0155] Example 3
[0156] 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-fluoropyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
[0157]
[0158] Step 1: N-[(2-fluoropyridin-4-yl)methyl]-3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine
[0159] To a stirred solution of 7-chloro-3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidine (1.1 g, 3.57 mmol) and 1-(2-fluoropyridin-4-yl)methylamine (0.586 g, 4.6 mmol) in ethanol (5.5 mL) was added diisopropylethylamine (5.5 mL, 5 volumes) and stirred at 80 ° C for 6 hours. After completion, the ethanol in the reaction was distilled off. The crude product was distributed between water and ethyl acetate. The ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure. The desired compound was eluted by flash column chromatography with 35% ethyl acetate-hexane. After concentration, N-[(2-fluoropyridin-4-yl)methyl]-3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidine-7-amine (0.9 g, 63.82%) was obtained as a light yellow compound.
[0160] Step 2: tert-Butyl [(2-fluoropyridin-4-yl)methyl](3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate To a stirred solution of N-[(2-fluoropyridin-4-yl)methyl]-3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine (0.5 g, 1.26 mmol) in dichloromethane (DCM) (5 mL) at 0°C was added 4-dimethylaminopyridine (DMAP) (0.153 g, 1.26 mmol). Boc anhydride (di-tert-butyl dicarbonate) (0.33 ml, 1.51 mmol) was then added dropwise at this temperature and stirred at ambient temperature for 2 hours. After completion, the reaction was washed with water. The organic layer was dried over Na2SO4 and concentrated. The crude product obtained was purified by flash column chromatography (neutral alumina) and the desired compound, [(2-fluoropyridin-4-yl)methyl](3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)carbamic acid tert-butyl ester (0.51 g, 82.2%) was eluted with 10% ethyl acetate-hexanes as an off-white solid.
[0161] Step 3: [3-(1,3-Dimethyl-1H-indazol-5-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(2-fluoro-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester
[0162] In a 25 ml round bottom flask was added tert-butyl [(2-fluoropyridin-4-yl)methyl](3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate (0.45 g, 0.904 mmol), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (0.322 g, 1.17 mmol), potassium carbonate (0.311 g, 2.26 mmol) and dioxane:water (4.5 mL:0.5 mL). The solution was degassed with N2 for 10 minutes and then Pd(dppf)Cl2.DCM complex (0.110 g, 0.135 mmol) was added. The reaction was heated at 100°C for 16 hours. Upon completion, the reaction was diluted with ethyl acetate and filtered through a bed of celite. The filtrate was partitioned between ethyl acetate and water. The ethyl acetate layer was dried over Na2SO4 and concentrated under reduced pressure. The crude product obtained was purified by flash column chromatography (neutral alumina) and the desired compound [3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(2-fluoro-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester (0.2 g, 42.9%) was eluted with 30% ethyl acetate-hexane as an off-white solid.
[0163] Step 4: 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-fluoropyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
[0164] To an ice-cold solution of [3-(1,3-dimethyl-1H-indazole-5-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(2-fluoro-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester (0.2 g, 0.388 mmol) in dichloromethane (2 mL) was added TFA (2 mL) dropwise. After the addition was complete, the reaction mass was stirred at ambient temperature for 6 hours. After the reaction was complete, the solvent and excess TFA were distilled off. The crude product was alkalized with 1N NaOH solution and extracted with 10% MeOH-DCM. The organic layer was dried over Na2SO4 and concentrated. The crude product obtained was purified by flash column chromatography (neutral alumina) and the desired compound Example 3 (0.06 g, 37.5%) was eluted with 70% ethyl acetate-hexane as an off-white solid.
[0165] Example 4
[0166] 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-methylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
[0167]
[0168] Step 1: 3-iodo-2,5-dimethyl-N-[(2-methylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
[0169] To a stirred solution of 7-chloro-3-iodo-2,5-dimethylpyrazolo[1,5-a]pyrimidine (1.1 g, 3.57 mmol) and 1-(2-methylpyridin-4-yl)methylamine (0.586 g, 4.6 mmol) in ethanol (5.5 mL) was added diisopropylethylamine (5.5 mL, 5 volumes) and stirred at 80 ° C for 6 hours. After completion, the ethanol in the reaction was distilled off. The crude product was partitioned between water and ethyl acetate. The ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure. The desired compound was eluted by flash column chromatography with 35% ethyl acetate-hexane. After concentration, 3-iodo-2,5-dimethyl-N-[(2-methylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidine-7-amine (0.9 g, 40.1%) was obtained as a light yellow compound.
[0170] Step 2: (3-iodo-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-(2-methyl-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester To a stirred solution of 3-iodo-2,5-dimethyl-N-[(2-methylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine (0.5 g, 1.26 mmol) in dichloromethane (5 mL) was added DMAP (0.153 g, 1.26 mmol) at 0°C. Boc anhydride (0.33 ml, 1.51 mmol) was then added dropwise at this temperature and stirred at ambient temperature for 2 hours. Upon completion, the reaction was washed with water. The organic layer was dried over Na2SO4 and concentrated. The crude product obtained was purified by flash column chromatography (neutral alumina) and the desired compound (3-iodo-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-(2-methyl-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester (0.51 g, 82.2%) was eluted with 10% ethyl acetate-hexane as an off-white solid.
[0171] Step 3: [3-(1,3-Dimethyl-1H-indazol-5-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(2-methyl-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester In a 25 ml round-bottom flask, (3-iodo-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-(2-methyl-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester (0.45 g, 0.904 mmol), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (0.322 g, 1.17 mmol), potassium carbonate (0.311 g, 2.26 mmol) and dioxane:water (4.5 mL:0.5 mL) were added. The solution was degassed with N2 for 10 minutes, and then Pd(dppf)Cl2.DCM complex (0.110 g, 0.135 mmol) was added. The reaction was heated at 100°C for 16 hours. After completion, the reaction was diluted with ethyl acetate and filtered through a celite bed. The filtrate was distributed between ethyl acetate and water. The ethyl acetate layer was dried over Na2SO4 and concentrated under reduced pressure. The obtained crude product was purified by flash column chromatography (neutral alumina), and the desired compound [3-(1,3-dimethyl-1H-indazole-5-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(2-methyl-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester (0.2 g, 43.4%) was eluted with 30% ethyl acetate-hexane as an off-white solid.
[0172] Step 4: 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-methylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
[0173] To an ice-cold solution of [3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(2-methyl-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester (0.2 g, 0.388 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (TFA) (2 mL) dropwise. After the addition was complete, the reaction mass was stirred at ambient temperature for 6 hours. After the reaction was complete, the solvent and excess TFA were distilled off. The crude product was alkalized with 1N NaOH solution and extracted with 10% MeOH-DCM. The organic layer was dried over Na2SO4 and concentrated. The crude product obtained was purified by flash column chromatography (neutral alumina) and the desired compound Example 4 (0.06 g, 37.7%) was eluted with 70% ethyl acetate-hexane as an off-white solid.
[0174] Examples 5-8 were synthesized using the same general method as described in Examples 3 and 4.
[0175] Example 5
[0176] 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-ethylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
[0177]
[0178] Example 6
[0179] 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-methoxypyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
[0180]
[0181] Example 7
[0182] 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-cyanopyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
[0183]
[0184] Example 8
[0185] 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-trifluoromethylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
[0186]
[0187] The analytical data of the compounds of Examples 1-8 are shown in Table 1.
[0188] Table 1
[0189]
[0190] Example 9
[0191] Liposome preparation
[0192] 50 mg of 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-fluoropyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine (Example 3) and 500 mg of soy lecithin were transferred to a beaker. Chloroform (about 10 ml) was added and the mixture was kept stirring until the components were completely dissolved. The solvent was then removed by a rotary evaporator to obtain a thin lipid film. Water (10 ml) was added to the lipid film and the film was rehydrated at room temperature. The preparation was thoroughly mixed and ultrasonicated to form a fine dispersion. The pH of the preparation was 6.42.
[0193] Biological assays
[0194] In vitro assays in mammalian cell culture
[0195] The antiviral activity of the compounds of the invention has been evaluated based on their ability to prevent viruses from causing viral cytopathic effects (CPE) in mammalian cell culture. Incubation times, cell lines, cell densities, and viral titers vary between different assays, but the general procedure is as follows: cells are cultured in 96-well flat-bottom plates to approximately 90% cell confluence (20 000-90 000 cells / well) in appropriate culture medium. Tissue culture infectious doses (TCID 50) standard method to determine the virus titer. In brief, cells were infected with 50 μL of virus suspension and diluted 10 times in culture medium. The plates were incubated at 37 ° C with 5% CO2 for 3-7 days, and the CPE of the cells was checked every day. After determining the CPE, the plates were stained with Gram's crystal violet solution and the optical density was read at 540nm. The highest virus dilution that resulted in> 95% CPE was used in the assay. Substances and viruses with a final concentration of 2.5-20 μM were added to the cells and incubated for 3-7 days according to the viruses and cell lines used. As a control. Uninfected cells and cells infected with the virus (without substance) were included on each plate. After determining the CPE on the infected control, the cells were stained with crystal violet and the optical density was read at 540nm. By comparing with the uninfected and infected controls, the inhibitory capacity was calculated in %.
[0196] The compounds of the invention of Examples 1-4 were tested using the above protocol. In addition, the same test was performed using compounds lacking a substituent at the 2-position of the pyridine ring (i.e., 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (Compound "X") and 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine (Compound "Y")):
[0197]
[0198]
[0199] Tables 2 and 3 show the inhibitory ability of the compounds tested at 10 nM and 100 nM, respectively, against different picornaviruses. EV6: enterovirus strain 6; EV30: enterovirus strain 30; EV-D68: enterovirus D68; EV71: enterovirus strain 71; Cox B1: coxsackie B virus strain 1; Cox B2: coxsackie B virus strain 2; Cox B3: coxsackie B virus strain 3; Cox B5: coxsackie B virus strain 5; Polio 1: poliovirus strain 1.
[0200] Table 2
[0201]
[0202] Table 3
[0203]
[0204] In vitro CYP 3A4 enzyme inhibition studies in human liver microsomes by a probe substrate approach
[0205] In vitro CYP 3A4 enzyme inhibition assay was performed using human liver microsomes at a concentration of 0.5 mg / mL. Ketoconazole was used as a reference inhibitor, while midazolam was used as a selective probe substrate for the CYP 3A4 enzyme. Serial dilutions of the test substance / control substance were prepared in potassium phosphate buffer (50 mM, pH 7.40) to obtain eight concentrations, each concentration being a 1:4 dilution pattern. The percentage of acetonitrile / DMSO was maintained at 2.5% / 0.25% in the control substance / test substance solution of the 2.5X serial dilution. The final percentages of acetonitrile / DMSO were 1% / 0.1% respectively. Intermediate solutions were prepared in potassium phosphate buffer, such as 10X working solution (5 mg / mL) human liver microsome solution, 10X concentration of reference probe substrate buffer, 5X concentration of cofactors (5.0 mM NADP+, 25.0 mM G-6-P, 3.0 IU / mL G-6-PDH and 10.0 mM MgCl2). The final concentration of liver microsomes in the reaction mixture was 0.5 mg / mL, and the cofactors were 1.0 mM NADP+, 5.0 mM G-6-P, 0.6 IU / mL G-6-PDH, and 2.0 mM MgCl2. Midazolam was tested at a 5 μM test concentration. 40 μL of the 2.5X serially diluted test / control solution and 10 μL of the 5X liver microsome solution were added to a 96-well plate and incubated at 37°C for 10 minutes under shaking conditions (400 rpm) using a Thermomixer. After pre-incubation, 20 μL of potassium phosphate buffer, 10 μL of the corresponding probe substrate working solution, and 20 μL of the cofactor mixture were added. The results are shown in Table 4, as IC 50 Expressed in μM.
[0206] Table 4
[0207]
[0208] Pharmacokinetic properties
[0209] Preparation
[0210] 10 mg of compound was weighed and transferred to a graduated tube. 500 μL DMA (5% v / v) was then added, vortexed thoroughly, and sonicated until the test article was completely dissolved. 5 mL of PEG 200 (50% v / v) was then added, and vortexed thoroughly. Thereafter, sterile water for injection (SWFI) was added in small increments and vortexed thoroughly. Finally, the volume was supplemented to 10 mL with SWFI (45% v / v) to obtain a clear solution with a final formulation strength of 1 mg / mL. The pH of the formulation was found to be 6.51. The formulation was freshly prepared before administration to the animals.
[0211] Dosage
[0212] Adult healthy male Sprague Dawley rats 8-10 weeks old were used for experiments after a minimum of 3 days of acclimatization.Fasted animals were administered test compounds by oral route at a dose of 10 mg / kg body weight and a dose volume of 10 mL / kg body weight in the recommended vehicle (5% DMA + 50% PEG 200 + 45% SWFI).
[0213] Under mild isoflurane anesthesia. At different time points after administration, blood samples were collected into pre-labeled tubes containing anticoagulants (K2EDTA, 2 mg / mL blood). The collected blood samples were centrifuged at 4000 rpm, 4°C for 10 minutes, and plasma was separated and stored at -80°C until analysis. The results are shown in Table 5.
[0214] Table 5
[0215] Compound Y Example 4 Example 3* Dosage (mg / kg bw,) 10 10 50 <![CDATA[C max (mg / mL)]]> 2.3±0.3 2.5±0.9 2.3±0.8 <![CDATA[T max (h)]]> 1.2±0.8 1.3±0.6 6±2 <![CDATA[AUC last (h*mg / mL)]]> 14.8±2.6 25.2±10.0 42.4±11.7 <![CDATA[AUC inf (h*mg / mL)]]> 15.5±1.9 27.4±10.1 129.8±55.8 <![CDATA[AUC extrap (%)]]> 4.6±5.6 8.5±5.2 64..5±13.5 <![CDATA[T 1 / 2 (h)]]> 3.4±1.2 6.8±1.5 41.5±19.7 <![CDATA[MRT last (h)]]> 4.4±1.1 6.7±0.6 11.3±0.5
[0216] *Liposome preparation
[0217] Metabolic stability
[0218] Metabolic stability assays were performed using human / rat liver microsomes. The final composition of the assay included 5 μM of test and control (diclofenac or imipramine) prepared from DMSO stock solutions, resulting in a final DMSO concentration of 0.1%, 0.25 mg / mL microsomal protein and cofactors (5.0 mM G-6-P, 0.06 U / mL G-6-PDH, 2.0 mM MgCl2, 1.0 mM NADP + ). The test / control was incubated with human / rat liver microsomes with and without cofactors. The reaction mixture (100 μL) was removed at the specified time and the reaction was terminated by adding stop solution. The samples were extracted in the presence of internal standard and analyzed using LC-MS / MS. The percentage of the test / control remaining after the specified incubation time relative to the peak area ratio at 0 minutes was calculated.
[0219] Brief plan
[0220] 4X working concentrations of test (20 μM) / control (20 μM) were prepared using 5 mM DMSO stock in 50 mM potassium phosphate buffer (pH 7.4).
[0221] Using human / rat liver microsome stock solution (20 mg / mL protein concentration), a 10X working concentration of human / rat liver microsome solution (2.5 mg / mL) was prepared in 50 mM potassium phosphate buffer (pH 7.40). 100 μL (for each time point) of the reaction mixture was incubated by adding 45 μL potassium phosphate buffer, 10 μL diluted human / rat liver microsome solution (2.5 mg / mL), 25 μL test / control (20 μM) and 20 μL cofactor / buffer. The reaction mixture was further incubated at 37°C for the specified incubation time points (with cofactor: 0, 15, 30, 60 and 120 minutes; without cofactor: 0 and 120 minutes). At the specified incubation time points, 100 μL of the incubation samples of the test and control were transferred to the corresponding tubes for sample extraction.
[0222] Protein precipitation extraction method
[0223] Test and control samples were extracted by protein precipitation. At each time point, 100 μL of incubation samples were added to a tube containing 200 μL of ice-cold acetonitrile and 50 μL of haloperidol solution (0.5 μg / mL). The tube was then fully vortexed and centrifuged at 10,000 rpm for 10 minutes at 4°C. The clarified supernatant of 200 μL of sample was subjected to LC-MS / MS analysis. The results are shown in Table 6, expressed as % remaining after incubation for 60 minutes.
[0224] Table 6
[0225] Compound Human microsomes Rat microsomes Compound Y 86.2% 89.7% Example 3 96.1% 99.4% Example 4 90.0% 84.0%
[0226] Human and rat plasma protein binding
[0227] method
[0228] Plasma protein binding studies were performed using a rapid equilibrium dialysis (RED) device containing a dialysis membrane with a molecular weight cutoff of 8,000 Daltons. Each dialysis insert contained two chambers. The red chamber was used for plasma, while the white chamber was used for buffer. Test and control substances (warfarin and propranolol) were prepared in human / rat plasma (pH adjusted to 7.40) at the desired test concentration of 10 μM using a 10mM DMSO stock solution (final DMSO concentration of 0.1%). 300 μL of plasma sample was added to the sample chamber. 500 μL of buffer was added to the buffer chamber. After sealing the RED device with an adhesive film, incubate at 37°C for 4 hours with 300 rpm shaking. After incubation, a 50 μL aliquot was removed from each well (plasma and buffer sides) and diluted with an equal volume of the opposite matrix to eliminate matrix effects, and sample extraction was performed.
[0229] Protein precipitation extraction method
[0230] All samples were extracted by protein precipitation by adding 200 μL of ice-cold acetonitrile and 50 μL of internal standard (haloperidol, 0.1 μg / mL) solution. The tubes were fully vortexed and centrifuged at 10000 rpm for 10 minutes at 4°C. The clarified supernatant of 200 μL samples was subjected to LC-MS / MS analysis. The results are shown in Table 7, expressed as % plasma protein binding.
[0231] Table 7
[0232] Compound Human plasma Rat plasma Compound Y 97.3% 97.6% Example 3 97.8% 94.1% Example 4 98.5% 98.3%
Claims
1. Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein One of X and Y is C and the other is N; R1 is selected from halogen, CN, C1-C4 alkoxy optionally substituted by 1-3 halogens and C1-C4 alkyl optionally substituted by 1-3 halogens or CN; and R2 is 3,4-dimethoxyphenyl or 1,3-dimethyl-1H-indazol-5-yl. 2 . The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is 3,4-dimethoxyphenyl.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 is 1,3-dimethyl-1H-indazol-5-yl.
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from halogen, CN, C1-C4 alkoxy optionally substituted by 1-3 halogens, and C1-C4 alkyl optionally substituted by 1-3 halogens.
5. The compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from F, CN, methoxy, methyl, trifluoromethyl and ethyl.
6. The compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from halogen and C1-C4 alkyl optionally substituted by 1-3 halogens.
7. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from F, methyl, trifluoromethyl and ethyl.
8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is N, and Y is C. 9 . The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is C and Y is N.
10. The compound according to claim 1, which is selected from 3-(3,4-dimethoxyphenyl)-2,6-dimethyl-N-((2-methylpyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine, 3-(3,4-dimethoxyphenyl)-N-((2-fluoropyridin-4-yl)methyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-amine, 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-fluoropyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-methylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-ethylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-methoxypyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-cyanopyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine, and 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-trifluoromethylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine, or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 1, which has the structural formula 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-methylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine, or a pharmaceutically acceptable salt of the compound.
12. A pharmaceutical composition comprising the compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable excipient.
13. Use of a compound or a pharmaceutically acceptable salt according to any one of claims 1 to 11 in the manufacture of a medicament for treating a viral infection, wherein the viral infection is an RNA viral infection.
14. The use according to claim 13, wherein the RNA virus infection is a picornavirus infection.
Citation Information
Patent Citations
Tetrazine bicyclic compounds
US6313124B1
Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010086040A1
Pyrazolo[1,5-a]pyrimidin-7-amine derivatives useful in therapy
WO2015110491A2
Heteroaromatic compounds useful in therapy
WO2018185120A1
Piperidine substituted pyrazolo[1,5-A]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)
CN107001377A
